Eli Lilly and Company
LLY
|
$726.31
-2.63%
-0.04%
3.5M
|
Health Technology
(0.0% 1d) (-2.9% 1m) (100.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-100.0% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 690,113,943,132
http://www.lilly.com
Sec Filling | Patents | 33625 employees
(US) Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Drugs
Alimta (Pemetrexed disodium)Amyvid (Florbetapir F 18)
Bamlanivimab (Bamlanivimab)
Baqsimi (glucagon)
BASAGLAR KwikPen (Insulin glargine)
BASAGLAR Tempo Pen (Insulin glargine)
Cialis (Tadalafil)
Cymbalta (Duloxetine hydrochloride)
CYRAMZA (ramucirumab)
Effient (Prasugrel hydrochloride)
EMGALITY (galcanezumab-gnlm)
Etesevimab (Etesevimab)
Evista (Raloxifene hydrochloride)
Forteo (Teriparatide)
Gemzar (Gemcitabine hydrochloride)
Glucagon (glucagon)
Humalog (Insulin lispro)
Humalog Junior KwikPen (Insulin lispro)
Humalog KwikPen (Insulin lispro)
Humalog Mix50/50 (Insulin lispro)
Humalog Mix50/50 KwikPen (Insulin lispro)
Humalog Mix75/25 (Insulin lispro)
Humalog Mix75/25 KwikPen (Insulin lispro)
Humalog Tempo Pen (Insulin lispro)
HUMATROPE (Somatropin)
Humulin 70/30 (Insulin human)
Humulin 70/30 KwikPen (Insulin human)
Humulin N (Insulin human)
Humulin R (Insulin human)
Humulin R U-500 (Insulin human)
Humulin R U-500 KwikPen (Insulin human)
Insulin Lispro (Insulin lispro)
Insulin Lispro Junior KwikPen (Insulin lispro)
Insulin Lispro KwikPen (Insulin lispro)
Insulin Lispro Protamine and Insulin Lispro Injectable Suspension Mix75/25 KwikPen (Insulin lispro)
LARTRUVO (olaratumab)
LYUMJEV (Insulin lispro-aabc)
LYUMJEV Junior KwikPen (Insulin lispro-aabc)
LYUMJEV KwikPen (Insulin lispro-aabc)
LYUMJEV Tempo Pen (Insulin lispro-aabc)
Olumiant (baricitinib)
Portrazza (necitumumab)
RETEVMO (selpercatinib)
Reyvow (lasmiditan)
Sterile Diluent (diluent)
Strattera (Atomoxetine hydrochloride)
Symbyax (Olanzapine and Fluoxetine hydrochloride)
TALTZ (ixekizumab)
TAUVID (Flortaucipir F-18)
Trulicity (Dulaglutide)
Verzenio (abemaciclib)
Zyprexa (Olanzapine)
ZYPREXA Intramuscular (Olanzapine)
ZYPREXA Relprevv (Olanzapine pamoate)
ZYPREXA Zydis (Olanzapine)
add to watch list Paper trade email alert is off
Press-releases
Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 15:00) - prnewswire.com
NVO | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
GSK | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.21%
H: 0.0%
C: 0.0%
AZN | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
report reach therapeutics market
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
Published: 2024-04-17 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.81%
H: 0.0%
C: 0.0%
biotech
Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity
Published: 2024-04-17 (Crawled : 11:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.03%
H: 1.66%
C: -1.11%
obesity tirzepatide
Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Published: 2024-04-16 (Crawled : 15:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
announcement conference for financial results
CARGO Therapeutics Names Kapil Dhingra, M.B.B.S., to Board of Directors
Published: 2024-04-15 (Crawled : 20:00) - globenewswire.com
CRGX | $19.16 0.31% 0.31% 200K
|
|
| O: -1.76%
H: 6.0%
C: 2.35%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.09%
H: 0.0%
C: 0.0%
BDTX A | $5.26 -0.76% -0.76% 390K
|
Health Technology
|
| O: 0.57%
H: 2.86%
C: 2.48%
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: 0.0%
H: 2.04%
C: -0.82%
therapeutics
Usher Syndrome Market to Exhibit Growth at a CAGR of 10.55% by 2034 | DelveInsight
Published: 2024-04-11 (Crawled : 22:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: -8.65%
H: 3.19%
C: 1.6%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.0%
H: 0.52%
C: -1.04%
growth market
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
Published: 2024-04-11 (Crawled : 05:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.06%
H: 0.47%
C: -0.03%
fda device disease test granted blood designation for alzheimer's roche
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
drug preclinical meeting
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
Published: 2024-04-09 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -2.01%
H: 0.0%
C: 0.0%
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
BIO | News | $279.73 -0.46% 0.0% 290K
|
Health Technology
|
| O: -2.71%
H: 0.52%
C: 0.24%
AVTR | $24.1 -0.82% 0.25% 4.7M
|
Process Industries
|
| O: -1.7%
H: 1.08%
C: 0.55%
THMO | $0.6695 3.0% 2.91% 8.6K
|
Health Technology
|
| O: 4.99%
H: 2.78%
C: -2.1%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
global growth market
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
ORIC | $9.2 -3.26% -3.37% 670K
|
Health Technology
|
| O: -2.81%
H: 1.54%
C: -3.57%
NRIX 2 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
therapeutics
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 1070000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT | News P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA | $0.377 -1.4% 97K
|
Health Technology
|
22:00
CLSD | $1.29 -2.27% -2.33% 230K
|
Health Technology
|
14:00
CDZI P 25000 | $2.25 0.0% 260K
|
Utilities
|
14:00
ETST P 39000 | $0.068 -67.14% 43K
|
Manufacturing
|
13:30
FNLC P 1275 | $22.97 3.66% 3.53% 21K
|
Finance
|
12:30
ADMQ | $0.0532 -40.18% 480K
|
|
10:30
AXR P 2400 | $21.0 -5.28% 0.0% 13K
|
Finance
|
21:00
QCRH P 118 | $57.315 3.44% 3.32% 66K
|
Finance
|
18:01
VUZI P 7500 | $1.19 -5.56% -5.88% 550K
|
Electronic Technology
|
18:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10